Philipp Kaufmann is Professor and Chair of Nuclear Medicine and Director of Cardiac Imaging at the University Hospital Zurich (USZ) where he is also chairing the conference of the chairs of department and serves as Director of the USZ Airport.
He is board certified in cardiology, nuclear medicine, and internal medicine. His research interests include noninvasive cardiac imaging, new algorithms for assessing coronary artery disease and plaque characterization. The cardiac imaging group led by Philipp Kaufmann published a large number of papers evaluating the diagnostic performance of nuclear tests, cardiac computer tomography and hybrid imaging. He currently serves as Associate Editor of the Journal of Nuclear Medicine and of the European Heart Journal – Cardiovascular Imaging and on the editorial board of the European Heart Journal and the Journal of Nuclear Medicine.
Markus G. Manz
Markus G. Manz is Professor of Hematology at the University of Zurich and Director of the department of Medical Oncology and Hematology at the University Hospital Zurich. He also chairs the Leukemia-, Lymphoma- and Myeloma-Center at the Comprehensive Cancer Center Zurich (in which he is part of the board of directors). Markus Manz’s research focusses on the biology of hematopoietic stem and progenitor cells and their malignant counterparts with the aim to develop and improve therapies. He serves as member of multiple societies/committees and is recipient of national and international prices.
Roland Martin is full professor for neurology and neuroimmunology at the University of Zurich. Roland Martin trained in medicine, and specialized in neurology at the University Würzburg. He pursued post-doctoral fellowships in immunology, virology and neuroimmunology in Würzburg and at the Neuroimmunology Branch, National Institutes of Health (NIH), Bethesda, USA, where he worked as tenured senior investigator until 2005. The main interests of his group are disease mechanisms of multiple sclerosis (MS), cellular immunology and developing novel treatments for MS besides providing care for MS patients in one of the largest MS centers in Switzerland. He has received several awards, among them a Heisenberg professorship of the German Research Society and the Pette Award of the German Neurological Society. He published over 360 scientific articles and filed numerous patents in the above areas. He is a member of the Kuratorium of the Jung Foundation for Science.
Brad Nelson has been the Professor of Robotics and Intelligent Systems at ETH Zurich since 2002, where his research focuses on micro and nanorobotics with primary applications in medicine and biology. He serves on advisory boards of a number of academic departments and research institutes across North America, Europe, and Asia, on editorial boards of several academic journals, and on the board of directors of three Swiss companies. He has been the Department Head of Mechanical and Process Engineering at ETH Zurich, Chairman of the ETH Electron Microscopy Center, and is a member of the Research Council of the Swiss National Science Foundation. He has received a number of awards for his work in robotics, nanotechnology, and biomedicine. Prior to ETH Zurich, Brad Nelson worked as an engineer at Honeywell and Motorola, as a United States Peace Corps Volunteer in Botswana, Africa, and was a professor at the University of Minnesota and the University of Illinois at Chicago.
Roger M. Nitsch
Roger M. Nitsch is a Professor of Molecular Psychiatry at the University of Zurich where he directs the Division of Psychiatry Research. A neuroscientist with a background in medicine, his scientific work includes the development of disease-modifying therapeutic approaches for neurodegenerative diseases. Together with his team, he pioneered the development of Aducanumab, a human monoclonal antibody currently in advanced clinical trials, together with Biogen, for the treatment of Alzheimer's disease. He is a co-founder and President of Neurimmune Holding AG, a biopharmaceutical company that develops recombinant human monoclonal antibodies for unmet medical needs. The Potamkin Prize winner, and Member of the German Academy of Sciences, serves as Editor-in-Chief for Neurodegenerative Disease, and as Executive Organizer of the AD/PD meetings. Roger M. Nitsch held prior research positions at M.I.T., MGH / Harvard Medical School, and the University of Hamburg. He was a fellow at the Max-Planck-Institute for Medical Research in Heidelberg, and received an MD from University of Heidelberg.
Robert Riener is full professor for Sensory-Motor Systems at the Department of Health Sciences and Technology, ETH Zurich, and full professor of medicine at the University Hospital Balgrist, University of Zurich. His research focuses on sensory-motor interactions between humans and machines. This includes the study of human motor recovery and learning, the development of rehabilitation robots and virtual reality technologies, and the investigation of human-machine interaction. Robert Riener is the initiator and organizer of the Cybathlon, which was honored with the European Excellence Award and the Yahoo Sports Technology Award. He has authored and co-authored more than 400 peer-reviewed journal and conference articles, and is inventor or co-inventor of more than 20 patents, and he has received many personal distinctions and awards. He is an editorial member of several international journals and serves on advisory boards of a number of national and international funding agencies, foundations and companies. He was the head of the Department of Health Sciences and Technology, ETH Zurich, and he is the deputy head of the National Competence Center in Research of Robotics. Prior to his time in Zurich, Robert Riener was postdoctoral researcher at TU München, Germany, and Polytecnico di Milano, Italy. He did his Habilitation in Biomechatronics and his PhD in Neuroprosthetics both at TU München in 2003 and 1997, respectively.
Wendelin J. Stark develops nanomaterial-based solutions for industrial and medical markets. He has commercialized over 20 products and cofounded six companies: Turbobeads GmbH makes magnetic chemicals (partially distributed by Sigma-Aldrich) and diagnostic metal nanomagnets. Nanograde AG provides over 1 Million customized nanoparticles for organic photovoltaics, sensors, and the chemical industry. FlamePowders AG has made large scale oxide nanopowders (stopped operation in 2006). (Bio)medical companies include smartodont GmbH (bioactive polymer implants, e.g. root canal treatments, 3D printed model teeth), novamem GmbH (water purification, nanofiltration), and Zurich Biomaterials GmbH (“bone wool”, an easy to shape dental and maxillofacial biomaterial). Wendelin J. Stark has formulated key mechanisms in nanomaterial/biology interactions that today form the regulatory basis for industrial nanotech products in Switzerland. He is inventor in > 20 patents and author of > 220 scientific articles. He is one of the most cited scientists globally (Thomson Reuters), and invited member of the New York Academy of Sciences.
Viola Vogel is a Professor in the Department of Health Science and Technology heading the Laboratory of Applied Mechanobiology at ETH Zurich, Switzerland. Trained as a Physicist and with her graduate research conducted at the Max-Planck Institute for Biophysical Chemistry, she spent two years as postdoctoral fellow at the University of California Berkeley. As faculty member, she joined the Department of Bioengineering at the University of Washington/Seattle in 1990 and moved there through the ranks to Full Professor. She was the Founding Director of the Center for Nanotechnology at the University of Washington (1997-2003) prior to her move to Switzerland in 2004. She exploits nanotechnology tools to decipher how bacteria and mammalian cells exploit mechanical forces to recognize and respond to material properties and their native environments. Her discoveries in single molecule and cell mechanics and how protein stretching switches their function, as well as in the field of mechanobiology have a wide range of technical and medical implications. In collaboration with clinicians, several technologies are currently carried towards preclinical studies.